At the news
? NEUTRALIMPACT 3/10 144 filed Apr 15, 2026 at 16:51 ET
Two institutional affiliates of Atlas Venture, Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., filed notices to sell a combined 3,135 shares of Kymera Therapeutics (KYMR) stock, valued at approximately $281,742. The filings were submitted on the same day, signaling coordinated intent to divest small positions.
- Atlas Venture Fund X, L.P. intends to sell 2,750 shares, valued at $247,142.50.
- Atlas Venture Opportunity Fund I, L.P. intends to sell 385 shares, valued at $34,599.95.
- Total proposed sale: 3,135 shares worth $281,742.45.
- Sales are planned through Merrill Lynch on Nasdaq, with filing dates of April 15, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access